Nicotine, Inflammation and Immune Signaling
Human Research, Nicotine Patches and Gum, the Cholinergic Anti-Inflammatory Pathway, α7 Receptors and the Conversation Between the Nervous and Immune Systems
Inflammation is one of the body's most sophisticated communication systems.
Immune cells release chemical messengers. Nerves carry information. Tissues respond. The brain receives signals from the body and sends signals back.
Modern research has revealed that the nervous system and immune system are deeply interconnected.
One of the most fascinating discoveries within this field involves the cholinergic anti-inflammatory pathway, a regulatory network through which neural signaling can influence immune activity.
At the center of much of this research is the:
α7 nicotinic acetylcholine receptor, or α7 nAChR.
Nicotine, a naturally occurring alkaloid produced by the tobacco plant, interacts with nicotinic acetylcholine receptors. Through these receptor systems, researchers have investigated nicotine's relationship with immune cells, cytokines, inflammatory signaling and neuroimmune communication.
And importantly, this story is not built entirely on laboratory cells or experimental models.
Human beings have been studied.
Nicotine patches have been investigated in randomized trials involving active ulcerative colitis.
Nicotine gum has been investigated in controlled human crossover research.
Researchers have administered nicotine patches to healthy nonsmokers and then examined cytokine production from their immune cells.
Human volunteers have received transdermal nicotine before a controlled inflammatory challenge.
Human intestinal tissue has been examined.
People with pulmonary sarcoidosis have participated in controlled transdermal nicotine research.
These studies give the nicotine-and-inflammation story something especially valuable:
a human foundation.
Focus of This Discussion
This page concerns:
Nicotine as a naturally occurring tobacco alkaloid
Nicotine patches
Nicotine gum
Controlled transdermal nicotine
Measured nicotine preparations used in research
Human nicotine research
Nicotinic acetylcholine receptors
α7 nicotinic acetylcholine receptors
Cholinergic immune signaling
The cholinergic anti-inflammatory pathway
Cytokines
Macrophages and monocytes
T cells and regulatory T cells
Toll-like receptors
Human inflammatory-response research
Active ulcerative colitis
Pulmonary sarcoidosis
Intestinal inflammation
Neuroinflammation
Microglia
Pain signaling
Experimental myocarditis research
Older medical literature
Dr. Bryan Ardis and the modern nicotine conversation
Human research discussed on this page includes both nicotine patches and nicotine gum.
Transdermal nicotine patches account for the larger body of controlled clinical research discussed here, while smaller controlled human studies have also investigated nicotine gum.
The focus is nicotine itself, the receptor systems it influences and what human and experimental research has revealed about inflammation and immune communication.
What Has Actually Been Demonstrated in Humans?
Before traveling deeper into receptors, cytokines and molecular pathways, it is worth looking directly at the people who participated in nicotine research.
Nicotine Patches and Active Ulcerative Colitis
Randomized human trials found greater clinical improvement with transdermal nicotine than placebo in active ulcerative colitis.
In one landmark trial:
17 of 35 people receiving transdermal nicotine achieved complete remission
compared with
9 of 37 receiving placebo.
Participants receiving nicotine also demonstrated greater improvement in clinical disease grade, histological grade, stool frequency, abdominal pain and fecal urgency.
Another randomized trial reported clinical improvement in:
12 of 31 people receiving transdermal nicotine
compared with
3 of 33 receiving placebo.
That is approximately:
39% with nicotine
compared with
9% with placebo.
Nicotine Gum and Active Ulcerative Colitis
Controlled human research has also investigated nicotine gum.
Seven nonsmoking people with ulcerative colitis participated in randomized, double-blind individual crossover trials comparing nicotine gum with placebo gum.
Three participants demonstrated sufficient improvement for nicotine gum to subsequently be incorporated into their treatment regimens.
All three responders were former smokers.
Human Immune Signaling
Controlled research involving healthy nonsmokers has demonstrated that transdermal nicotine can influence cytokine production from human immune cells.
Researchers administered nicotine and subsequently collected immune cells from participants' blood.
A significant change in IL-2 production was documented.
This creates a remarkably direct research sequence:
person → nicotine patch → blood → immune cells → measurable cytokine change
A Whole-Body Human Inflammatory Challenge
Researchers have also investigated what happens when nicotine is present during a deliberately induced inflammatory response.
Twelve healthy adult men participated.
Six received a 7 mg transdermal nicotine patch before receiving a carefully controlled dose of bacterial endotoxin.
Compared with the control group, the nicotine group demonstrated:
A significantly lower fever response
Attenuated cardiovascular responses
Increased circulating IL-10
Increased cortisol
The researchers described the findings as a more prominent anti-inflammatory phenotype.
This gives us something especially valuable:
nicotine patch → human being → inflammatory challenge → measurable whole-body response
Human Intestinal Tissue
Researchers studying nicotine and ulcerative colitis have also examined inflammatory activity within intestinal tissue.
This connects the clinical experience of participants with biological changes occurring within affected tissue.
Pulmonary Sarcoidosis
Nicotine has also been investigated in people with active pulmonary sarcoidosis.
A pilot randomized, double-blind trial involving 50 adults examined transdermal nicotine over 24 weeks and measured pulmonary function.
This provides another human inflammatory-disease chapter in the nicotine research story.
Taken together, these studies move the subject beyond receptor theory.
People received nicotine.
Their symptoms were recorded.
Their immune cells were examined.
Their tissues were studied.
Their inflammatory responses were measured.
Their physiological responses were documented.
Inflammation Is Communication
Inflammation is often imagined simply as redness, swelling, heat or pain.
Biologically, it is much more sophisticated.
Inflammation is communication.
Immune cells detect changes within the body.
Chemical messengers are released.
Other immune cells are recruited.
Blood vessels respond.
Nerve endings become more sensitive.
Tissues alter their behavior.
The brain receives information about what is happening.
Neurological and hormonal signals return to the body.
Among the most important messengers involved in this process are cytokines.
These include:
TNF-α
IL-1β
IL-2
IL-6
IL-8
IL-10
IL-17
Interferons
Different cytokines perform different jobs.
Some help initiate inflammatory responses.
Some recruit additional immune cells.
Some regulate immune-cell growth and activation.
Others participate in controlling inflammatory activity.
The body continually adjusts this chemical conversation.
Nicotine research has helped reveal that nicotinic acetylcholine receptors participate in that regulation.
The Nervous and Immune Systems Are Connected
The nervous system and immune system were once frequently described as largely separate biological worlds.
Neuroimmunology has transformed that picture.
The brain receives information about immune activity.
Peripheral nerves communicate with immune tissues.
Immune cells possess receptors capable of responding to neurotransmitters.
Neurotransmitters can influence immune-cell behavior.
Immune signaling, in turn, can influence the nervous system.
This continuous exchange is known broadly as neuroimmune communication.
One of the most fascinating discoveries within this field is cholinergic regulation of inflammation.
Acetylcholine, the body's natural neurotransmitter for nicotinic receptors, communicates through receptor systems involved throughout the body.
Nicotine interacts with many of these same nicotinic receptors.
That creates an extraordinary biological bridge:
nervous system → cholinergic signaling → nicotinic receptors → immune cells → inflammatory signaling
The Cholinergic Anti-Inflammatory Pathway
The cholinergic anti-inflammatory pathway describes biological circuitry through which cholinergic signaling participates in regulating inflammatory activity.
Research has focused extensively on communication involving the nervous system, acetylcholine and nicotinic receptors expressed by immune-related cells.
One receptor has received exceptional attention:
α7 nicotinic acetylcholine receptor.
Activation of α7-related pathways can alter intracellular signaling within immune cells.
Research has connected this receptor system with inflammatory mediators including:
TNF-α
IL-1β
IL-6
IL-17
HMGB1
Nicotine became an important research tool because it interacts with nicotinic receptors involved in this network.
The α7 Nicotinic Acetylcholine Receptor
The α7 receptor occupies an extraordinary position within biology.
It occurs within the nervous system, while α7-related signaling also appears throughout immune and inflammatory research.
Scientists have investigated α7 pathways involving:
Macrophages
Monocytes
Microglia
T-cell signaling
Intestinal immune cells
Neural cells
Cardiovascular tissues
Pulmonary inflammatory pathways
That places α7 receptor biology at an intersection between:
neurology
immunity
inflammation
tissue regulation
Nicotine's interaction with nicotinic receptors has therefore helped scientists investigate much more than neurological stimulation.
It has helped illuminate how the body regulates inflammatory communication.
Human Immune Cells Respond to Transdermal Nicotine
One of the clearest pieces of evidence comes directly from human participants.
A randomized, double-blind, placebo-controlled study involved 24 healthy nonsmokers.
Twelve received transdermal nicotine and twelve received placebo.
Nicotine was gradually increased to 15 mg per day.
After two weeks, researchers collected immune cells from participants' blood and measured cytokine production.
Transdermal nicotine significantly inhibited IL-2 production.
This creates a remarkably direct human research sequence:
person
↓
nicotine patch
↓
blood collected
↓
immune cells studied
↓
cytokine production measured
↓
significant IL-2 change observed
The result is direct human evidence connecting nicotine exposure with measurable immune signaling.
What Is IL-2?
Interleukin-2 is an important immune signaling molecule.
IL-2 helps regulate the activation, proliferation and communication of T cells.
T cells are central participants in adaptive immunity.
Because IL-2 participates in immune-cell activation and proliferation, changes in its production can influence the organization and intensity of immune responses.
The human transdermal nicotine study therefore provides an important bridge between nicotine exposure and measurable human immune-cell activity.
Nicotine and a Whole-Body Human Inflammatory Response
The human endotoxin experiment adds another dimension.
Instead of examining only isolated cells, researchers created a temporary, carefully controlled inflammatory challenge in healthy volunteers.
Six participants received a 7 mg nicotine patch.
Six served as controls.
After endotoxin exposure, the nicotine group experienced a significantly lower temperature response and attenuated cardiovascular responses.
Researchers also observed increased circulating IL-10 and cortisol.
The study therefore demonstrates nicotine-related changes occurring at the level of the whole human organism.
The immune system, nervous system, endocrine system and cardiovascular system were participating in the same biological event.
This is a striking example of why inflammation cannot be understood as an isolated immune phenomenon.
Immune Cells Carry Nicotinic Signaling Machinery
Nicotinic receptor systems reach beyond neurons.
Immune-related cells contain components capable of responding to cholinergic signals.
Macrophages are especially important.
Macrophages help:
Recognize biological challenges
Remove damaged material
Coordinate inflammatory responses
Release cytokines
Communicate with other immune cells
Participate in tissue repair
α7 nicotinic receptor signaling can influence macrophage inflammatory activity.
This helped establish an important principle of modern neuroimmunology:
Neural signaling and immune-cell behavior are biologically connected.
Nicotine and the Immune Cell's Regulatory Machinery
The immune system contains internal mechanisms that regulate inflammatory signaling.
One important regulatory molecule is IRAK-M.
IRAK-M participates in controlling signaling initiated through Toll-like receptors.
Research using human macrophages has connected nicotine activation of α7 nicotinic receptors with IRAK-M expression through signaling involving:
α7 nAChR → JAK2 / PI3K → STAT3 → IRAK-M
Toll-like receptors help immune cells recognize biological signals and initiate inflammatory responses.
IRAK-M participates in regulating the strength of those responses.
This reveals another layer of the nicotine story.
Nicotinic signaling can reach into intracellular systems involved in determining how strongly immune cells respond to inflammatory stimulation.
Nicotine Patches and Active Ulcerative Colitis
One of the richest human chapters in medicinal nicotine research involves active ulcerative colitis.
Observations surrounding the condition led researchers to investigate whether nicotine itself could influence disease activity.
That question eventually produced randomized controlled human trials.
Landmark Randomized Trial
In a randomized, double-blind study, 72 people with active ulcerative colitis received transdermal nicotine or placebo for six weeks while continuing their established therapy.
The results were striking.
17 of 35 people receiving nicotine achieved complete remission
compared with
9 of 37 receiving placebo.
Nicotine-treated participants also demonstrated greater improvement in:
Overall clinical disease grade
Histological disease grade
Stool frequency
Abdominal pain
Fecal urgency
The study therefore documented both clinical and histological improvement.
The Human Findings Were Repeated
Another randomized, double-blind, placebo-controlled trial enrolled 64 nonsmoking people with mildly to moderately active ulcerative colitis.
Participants received transdermal nicotine or placebo.
Clinical improvement occurred in:
12 of 31 receiving nicotine
compared with
3 of 33 receiving placebo.
That equals approximately:
39% with nicotine
versus
9% with placebo.
The human evidence had therefore moved beyond a single clinical trial.
Nicotine Was Studied in Difficult-to-Treat Active Disease
Researchers also investigated transdermal nicotine in people with distal ulcerative colitis that had continued despite rectal mesalamine treatment.
Thirty participants were assigned to additional transdermal nicotine or additional oral mesalamine.
Remission occurred in 12 of 15 people receiving added transdermal nicotine compared with 5 of 15 receiving additional oral mesalamine.
This added another human clinical chapter to the nicotine-and-ulcerative-colitis story.
Nicotine Gum Has Also Been Studied in People
Transdermal patches account for most of the larger controlled clinical evidence on this page.
But nicotine gum also has a human research history worth preserving.
Researchers conducted randomized, double-blind crossover individual trials involving seven nonsmoking people with ulcerative colitis.
Participants received nicotine gum and placebo gum during alternating treatment periods.
They used up to 20 mg of nicotine gum per day during nicotine periods.
Researchers evaluated symptoms and the proctoscopic appearance of the affected colon.
Three of the seven participants demonstrated sufficient improvement for nicotine gum to subsequently be incorporated into their treatment regimens.
All three responders were former smokers.
This was a small study, but it gives us genuine controlled human evidence involving nicotine gum.
These were people.
Nicotine gum was compared with placebo gum.
Symptoms were evaluated.
The affected colon was examined.
And individual responders were identified.
The Ulcerative-Colitis Evidence Was Reviewed Together
Researchers later examined randomized transdermal nicotine trials collectively.
Across two placebo-controlled trials pooled for remission:
19 of 71 nicotine-treated participants entered remission
compared with
9 of 70 receiving placebo.
For improvement or remission:
29 of 71 receiving nicotine improved or entered remission
compared with
14 of 70 receiving placebo.
The combined evidence found transdermal nicotine superior to placebo for active mild-to-moderate ulcerative colitis.
The research story therefore developed across multiple levels:
early human observations
↓
controlled nicotine-gum research
↓
randomized nicotine-patch trials
↓
replication
↓
clinical remission
↓
histological assessment
↓
intestinal tissue research
↓
cytokine investigation
↓
systematic review
That is why active ulcerative colitis deserves such a prominent place on this page.
Pulmonary Sarcoidosis Adds Another Human Research Story
Pulmonary sarcoidosis involves granulomatous inflammation, in which immune cells organize into inflammatory clusters within affected tissues.
Nicotine research in this area has explored several immune systems, including:
T cells
Regulatory T cells
Macrophages
Toll-like receptors
Cytokine communication
Human research has investigated nicotine in relation to Toll-like receptor responsiveness and FoxP3-positive regulatory T cells.
A later pilot randomized, double-blind trial involving 50 adults with active pulmonary sarcoidosis investigated transdermal nicotine over 24 weeks.
Researchers measured pulmonary function, including forced vital capacity.
The research produced a measurable between-group FVC difference favoring transdermal nicotine.
This adds another human inflammatory condition to the nicotine research story.
Toll-Like Receptors and Nicotinic Signaling
Toll-like receptors, commonly abbreviated TLRs, form an important part of immune recognition.
They help cells detect molecular patterns associated with microbes, tissue damage and biological stress.
TLR activation can initiate inflammatory cascades.
Nicotinic receptor signaling intersects with this system at several levels.
Human sarcoidosis research has investigated TLR responsiveness.
Research using human macrophages has demonstrated α7-related regulation involving IRAK-M, an intracellular regulator of Toll-like receptor signaling.
This creates another biological connection:
nicotinic receptors ↔ Toll-like receptors ↔ intracellular regulation ↔ cytokines ↔ inflammatory response
Pain, Nicotinic Receptors and Human Research
Pain and inflammatory signaling are closely intertwined.
Inflammatory molecules can alter sensory-nerve activity, while nicotinic receptors participate in neurological pathways involved in pain perception.
Human researchers have therefore investigated transdermal nicotine around surgery.
Across randomized studies, nicotine patches have produced measurable analgesic findings in several settings and populations.
The broader research shows that responses vary according to the population, procedure and study design.
For this page, the important discovery is the biological connection:
nicotinic signaling participates in the conversation among nerves, pain and inflammatory physiology.
Nicotine, Neuroinflammation and the Brain
Inflammatory communication also occurs within the nervous system.
The brain contains immune-related cells called microglia.
Microglia continually monitor the neurological environment and participate in:
Defense
Tissue maintenance
Response to injury
Removal of damaged material
Cytokine production
Inflammatory signaling
α7 nicotinic receptor pathways have been investigated in relation to microglial activity.
This has led researchers to explore nicotinic signaling in:
Neuroinflammation
Cytokine production
Oxidative stress
Neural injury
Cognitive function
Neurological recovery
Neurodegenerative research
The same receptor family appearing in intestinal and peripheral immune research therefore also appears within the brain's immune environment.
Different tissues.
Different biological circumstances.
A shared signaling language.
Experimental Nicotine Research in Viral Myocarditis
The relationship between nicotinic signaling and cardiac inflammation has also been explored experimentally.
Researchers studying Coxsackievirus B3-induced viral myocarditis have investigated nicotine because of its interaction with α7 nicotinic acetylcholine receptors.
Experimental research has examined changes involving:
Myocardial inflammation
TNF-α
IL-1β
IL-6
IL-17A
Cardiac function
Intracellular immune signaling
STAT3 signaling
This research occupies the experimental evidence lane, separate from the human clinical findings discussed elsewhere on this page.
That distinction helps us understand what different types of research contribute.
Human studies reveal what happened in people.
Experimental studies allow researchers to explore the biological machinery underneath those observations.
Why the Same Receptor Appears Across Different Tissues
Ulcerative colitis.
Sarcoidosis.
Systemic inflammatory responses.
Neuroinflammation.
Myocardial inflammation.
At first glance, these subjects seem very different.
Underneath the disease names, however, biology uses shared signaling systems.
Immune cells travel.
Cytokines circulate.
Nerves reach multiple organs.
Receptors appear in many tissues.
The α7 nicotinic acetylcholine receptor can therefore participate in inflammatory regulation across very different biological environments.
The response is shaped by:
Cell type
Receptor subtype
Tissue environment
Existing inflammatory signals
Nicotine delivery method
Amount of receptor stimulation
Duration of receptor activation
The receptor language is shared.
The biological context shapes the response.
The Body Has Its Own Inflammation-Regulating Circuitry
This may be the most important idea on the entire page.
The human body contains sophisticated internal circuitry for regulating inflammation.
Nerves communicate with immune cells.
Acetylcholine interacts with receptors.
Receptors influence intracellular pathways.
Those pathways influence cytokines.
Cytokines alter the behavior of other cells.
The immune response changes.
Nicotine interacts with biological circuitry already present within the human body, giving researchers a remarkable window into how that circuitry regulates immune communication.
The nicotine molecule therefore becomes more than the subject of research.
It becomes one of the tools through which researchers have learned more about the human body's own regulatory systems.
Dr. Bryan Ardis and the Modern Nicotine Conversation
Dr. Bryan Ardis, D.C., deserves recognition within the contemporary conversation surrounding nicotine.
His contribution is different from that of the investigators who conducted the clinical and laboratory studies discussed on this page.
Researchers conducted the studies. Dr. Ardis has helped bring renewed public attention to portions of the nicotine literature.
His educational work has encouraged audiences to revisit subjects including:
Nicotine patches
Nicotine gum
Nicotinic acetylcholine receptors
Inflammation
Immune signaling
Neurological research
Myocarditis research
Older medical literature
The wider biological significance of nicotine
That distinction allows his contribution to be honored accurately.
An important medical paper can remain largely unknown outside a specialist field for decades.
Someone who draws public attention back to that literature can inspire people to rediscover questions, observations and research they had never encountered.
The ulcerative-colitis literature is an excellent example.
Some human nicotine studies receiving renewed attention today are more than three decades old.
Their age does not erase the people who participated, the measurements researchers made or the results they reported.
Older Medical Literature Still Matters
Newer does not automatically mean more meaningful.
Older does not automatically mean obsolete.
A well-designed randomized human trial remains part of the scientific record.
Earlier nicotine literature includes:
Controlled nicotine-gum research
Randomized nicotine-patch trials
Clinical outcomes
Histological examination
Intestinal tissue analysis
Cytokine measurements
Human inflammatory-response experiments
Modern researchers can revisit those observations using technologies that did not exist when many of the original studies were performed.
Today researchers have access to:
Advanced immune profiling
Single-cell analysis
Genetic analysis
Receptor mapping
Microbiome analysis
Advanced imaging
More precise cytokine measurement
Modern neuroimmunology
Sometimes newer science does not replace an older observation.
It helps us understand it more deeply.
What Human Nicotine Research Has Revealed
When we gather the human evidence together, the picture becomes clearer.
Nicotine Patches and Active Ulcerative Colitis
Randomized human trials demonstrated greater improvement and remission with transdermal nicotine than placebo in active ulcerative colitis.
Nicotine Gum
Controlled randomized crossover research documented individual responders with ulcerative colitis whose improvement was sufficient for nicotine gum to become part of their subsequent treatment regimens.
Human Immune Cells
Controlled transdermal nicotine exposure produced measurable changes in cytokine production from human immune cells.
Human Systemic Inflammation
A controlled human endotoxin experiment found that transdermal nicotine altered the whole-body inflammatory response, including a lower fever response and increased IL-10.
Pulmonary Sarcoidosis
A pilot randomized human trial investigated transdermal nicotine over 24 weeks and documented a measurable FVC difference favoring nicotine.
Neuroimmune Biology
Research involving α7 nicotinic acetylcholine receptors, macrophages, Toll-like receptors and microglia has helped illuminate the biological pathways connecting nicotinic signaling with inflammatory regulation.
There is laboratory science.
There is receptor biology.
There is experimental research.
And there are people.
That human evidence deserves to remain at the heart of this story.
How to Use This Information Wisely
Nicotine is biologically active, which is precisely why researchers have been able to study it across neurological, immune and inflammatory systems.
The human research discussed on this page includes nicotine patches and nicotine gum, with transdermal patches accounting for the larger controlled clinical literature covered here.
Research protocols have used particular nicotine preparations, amounts, schedules and carefully defined study populations for specific scientific questions.
The strongest human evidence on this page concerns particular research settings rather than a single universal protocol.
That makes the details important.
The preparation matters.
The amount matters.
The population matters.
The biological question matters.
The outcome researchers measured matters.
Preserving those details allows the findings to remain as powerful as the evidence itself.
A Remarkable Conversation Inside the Human Body
Perhaps the most important lesson from nicotine-and-inflammation research is what nicotine has helped reveal about the human body itself.
The nervous system talks to the immune system.
Immune cells respond to neurological signals.
Macrophages communicate with other immune cells.
Toll-like receptors recognize biological signals.
Cytokines carry messages from cell to cell.
The brain receives information from the body.
The body sends information back.
Nicotinic acetylcholine receptors sit within this extraordinary conversation.
And human beings have helped reveal it.
People volunteered for nicotine-patch trials.
People participated in nicotine-gum crossover experiments.
Researchers examined their symptoms.
Researchers studied their blood.
Researchers examined affected tissues.
Researchers challenged the human inflammatory response and measured what happened.
Researchers measured pulmonary function.
Decades later, those observations remain part of the scientific record.
Dr. Bryan Ardis has helped bring renewed public attention to nicotine research that many people had never encountered.
Modern neuroimmunology is providing increasingly sophisticated tools for understanding the receptor systems beneath those observations.
The nicotine-and-inflammation story is ultimately a story about communication: nerves talking to immune cells, immune cells talking to tissues, receptors receiving messages and the body continually regulating its internal environment through an extraordinary biological network.
There is still much more to discover.
Questions and Answers
What forms of nicotine are discussed on this page?
This page discusses nicotine patches, nicotine gum and controlled nicotine preparations used in research.
Transdermal nicotine patches account for most of the larger controlled human clinical studies discussed here.
Is there human research on nicotine patches and inflammation?
Yes.
Human research includes randomized trials involving active ulcerative colitis, controlled immune-cell research, a human inflammatory-challenge experiment and pulmonary sarcoidosis research.
Have nicotine patches helped people with active ulcerative colitis in randomized trials?
Yes.
Randomized controlled trials found greater clinical improvement with transdermal nicotine than placebo in active ulcerative colitis.
One landmark study reported complete remission in 17 of 35 nicotine-treated participants compared with 9 of 37 receiving placebo.
Was that finding repeated?
Yes.
Another randomized trial found clinical improvement in 12 of 31 nicotine-treated participants compared with 3 of 33 receiving placebo.
Has nicotine gum been studied in people?
Yes.
A randomized, double-blind crossover investigation studied nicotine gum in seven nonsmoking people with ulcerative colitis.
Three demonstrated sufficient improvement for nicotine gum to subsequently be incorporated into their treatment regimens.
Were the nicotine-gum responders former smokers?
Yes.
All three responders in that small controlled study were former smokers.
Has nicotine been shown to influence human immune cells?
Yes.
A randomized, placebo-controlled study involving healthy nonsmokers documented a significant change in IL-2 production following transdermal nicotine exposure.
What is IL-2?
IL-2 is an immune signaling molecule involved in T-cell activation, proliferation and communication.
Has nicotine been studied during an inflammatory challenge in humans?
Yes.
In a controlled human experiment, participants receiving a 7 mg nicotine patch before endotoxin exposure demonstrated a significantly lower fever response, attenuated cardiovascular responses and increased IL-10 and cortisol.
What is the cholinergic anti-inflammatory pathway?
The cholinergic anti-inflammatory pathway is a biological communication system through which cholinergic signaling participates in the regulation of immune and inflammatory activity.
What does nicotine have to do with this pathway?
Nicotine interacts with nicotinic acetylcholine receptors, including α7-related receptor pathways extensively investigated in immune regulation.
What is the α7 nicotinic acetylcholine receptor?
α7 nAChR is a nicotinic receptor involved in neurological and immune-related signaling.
It has become an important target in neuroimmunology and inflammatory research.
Do immune cells have nicotinic signaling systems?
Yes.
Nicotinic receptor components and cholinergic signaling mechanisms have been identified in multiple immune-related cell populations.
What are macrophages?
Macrophages are immune cells involved in detecting biological challenges, clearing damaged material, producing cytokines, coordinating inflammation and participating in tissue repair.
What are Toll-like receptors?
Toll-like receptors help immune cells recognize molecular patterns associated with microbes, tissue injury and biological stress.
Has nicotine been studied in pulmonary sarcoidosis?
Yes.
Human research includes a pilot randomized, double-blind trial involving 50 adults with active pulmonary sarcoidosis that investigated transdermal nicotine over 24 weeks.
Is nicotine involved in neuroinflammation research?
Yes.
Nicotinic receptors, particularly α7-related pathways, have been investigated in relation to microglia, cytokine signaling and neuroinflammation.
Has nicotine been researched in myocarditis?
Experimental research has investigated nicotine and α7 nicotinic receptor signaling in viral myocarditis models, including inflammatory cytokines, intracellular signaling and cardiac function.
Why is Dr. Bryan Ardis included on this page?
Dr. Bryan Ardis has helped bring nicotine patches, nicotine gum, nicotinic receptors and older nicotine research into wider contemporary discussion.
His contribution on this page is recognized as an educator drawing renewed public attention to research conducted by scientific investigators.
Why does older nicotine research matter?
Older randomized human trials and controlled experiments remain part of the scientific record.
Modern immunology and neurobiology can revisit their observations using technologies and biological knowledge that were unavailable when many of those studies were conducted.
What is the larger lesson from this research?
Nicotine interacts with receptor systems involved in communication between neurological and immune biology.
Human research has documented clinical outcomes, immune-cell changes and whole-body inflammatory-response findings, while experimental research has helped reveal receptor and intracellular pathways beneath them.
The deeper researchers explore nicotinic signaling, the more extraordinary the conversation between the nervous system, immune system and inflammatory response becomes.